P12497 (POL_HV1N5) Human immunodeficiency virus type 1 group M subtype B (isolate NY5)(HIV-1)
Gag-Pol polyprotein UniProtKBInterProInteractive Modelling
1435 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
375 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:dGTP ternary complex |
Heteromer | 1×MG; 1×DGT; 3×GOL; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:entecavir 5'-triphosphate ternary complex |
Heteromer | 3×GOL; 1×MG; 1×ET9; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:lamivudine 5'-triphosphate ternary complex |
Heteromer | 1×GLC; 1×1RZ; 1×MG; 2×GOL; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with Q151M/Y115F/F116Y:DNA:dCTP ternary complex |
Heteromer | 1×GLC; 1×DCP; 1×MG; 2×GOL; | ||||
| Assess | ||||||
| Structure of HIV-1 RT Q151M mutant |
Heteromer | |||||
| Assess | ||||||
| HIV-1 reverse transcriptase mutant Q151M/Y115F/F116Y/M184V/F160M:DNA:dCTP ternary complex |
Heteromer | 1×DCP; 2×GOL; 1×MG; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase mutant Q151M/Y115F/F116Y/M184V:DNA:dGTP ternary complex |
Heteromer | 1×DGT; 1×MG; 3×GOL; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with Q151M/Y115F/F116Y/M184V/F160M:DNA:lamivudine 5'-triphosphate terna… |
Heteromer | 1×GLC; 2×GOL; 1×1RZ; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with Q151M/G112S/D113A/Y115F/F116Y/F160L/I159L:DNA:dGTP ternary complex |
Heteromer D3XFN7; | 1×DGT; 1×MG; 2×GOL; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with Q151M/G112S/D113A/Y115F/F116Y/F160L/I159L:DNA:entecavir-triphospha… |
Heteromer D3XFN7; | 1×ET9; 2×GOL; 1×MG; | ||||
| Assess | ||||||
| Structure of Q148K HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K/G140S/Q148H HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of WT HIV-1 intasome bound to Dolutegravir |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K/G140A/Q148K HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K/G140A/Q148K HIV-1 intasome with 4d bound |
Heteromer | 2×OZ1; 4×MG; 2×ZN; | ||||
| Assess | ||||||
| Structure of E138K/Q148K HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K/G140A/Q148R HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K/G140A HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of G140A/Q148K HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of E138K HIV-1 intasome with Dolutegravir bound |
Heteromer | 4×MG; 2×ZN; 2×DLU; | ||||
| Assess | ||||||
| Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and INSTI XZ446 (comp… |
Heteromer | 2×MG; 2×ZN; 1×XXJ; | ||||
| Assess | ||||||
| Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and INSTI XZ426 (comp… |
Heteromer | 2×MG; 2×ZN; 1×OZ1; | ||||
| Assess | ||||||
| Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and INSTI XZ419 (comp… |
Heteromer | 2×MG; 2×ZN; 1×QUW; | ||||
| Assess | ||||||
| CryoEM structure of HIV-1 cleaved synaptic complex (CSC) intasome |
Heteromer | 4×MG; 2×DLU; | ||||
| Assess | ||||||
| Structure of HIV cleaved synaptic complex (CSC) intasome bound with magnesium and Bictegravir (BIC) |
Heteromer | 2×MG; 2×ZN; 1×KLQ; | ||||
| Assess | ||||||
| Structure of HIV cleaved synaptic complex (CSC) intasome bound with calcium |
Heteromer | 2×CA; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 capsid IP6-CPSF6 complex |
Heteromer Q16630; | 12×IHP; | ||||
| Assess | ||||||
| X-ray structure of pentameric HIV-1 CA |
Heteromer Q72497; | |||||
| Assess | ||||||
| Minimal 2:2 Ternary Complex between BI-224436 bound HIV-1 Integrase Catalytic Core Domain Dimer and… |
Heteromer | 2×L3D; 5×EDO; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 15×EDO; 2×WBV; 2×MG; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 10×EDO; 1×PEG; 2×U5S; 2×MG; 1×CL; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 14×EDO; 1×CL; 2×U5L; 2×MG; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 3×EDO; 5×PEG; 2×GOL; 2×LF0; 2×MG; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 2×RWR; 14×EDO; 1×CL; 2×MG; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 2×MG; 6×EDO; 2×723; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 2×W2Q; 5×EDO; 2×MG; 4×PEG; 1×CL; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain and C-Terminal Domain in Complex with Allosteric Integrase In… |
Heteromer | 1×CL; 7×EDO; 2×U60; 2×MG; 1×PGE; | ||||
| Assess | ||||||
| Structural basis for the recognition between HIV-1 integrase and LEDGF/p75 |
Heteromer O75475; | 2×PO4; 4×GOL; | ||||
| Assess | ||||||
| HIV-1 CAPSID PROTEIN (P24) COMPLEX WITH FAB25.3 |
Heteromer Q99LC4; | 2×PB; | ||||
| Assess | ||||||
| X-ray crystal structure of Cyclophilin A/HIV-1 CA N-terminal domain (1-146) O-type chimera Complex. |
Heteromer P62937; | |||||
| Assess | ||||||
| acetyl-CypA:HIV-1 N-term capsid domain complex |
Heteromer P62937; | |||||
| Assess | ||||||
| TRIMCyp cyclophilin domain from Macaca mulatta: HIV-1 CA(O-loop) complex |
Heteromer P62940; | |||||
| Assess | ||||||
| Crystal structure of HIV-1 capsid N-terminal domain in complex with NUP358 cyclophilin |
Heteromer P49792; | |||||
| Assess | ||||||
| HUMAN CYCLOPHILIN A BOUND TO THE AMINO-TERMINAL DOMAIN OF HIV-1 CAPSID |
Heteromer P62937; | |||||
| Assess | ||||||
| TRIMCyp cyclophilin domain from Macaca mulatta: H70C mutant, HIV-1 CA(O-loop) complex |
Heteromer P62940; | |||||
| Assess | ||||||
| Crystal structure of the HIV-1 capsid protein C-terminal domain in complex with a camelid VHH and t… |
Heteromer | 3×ACT; | ||||
| Assess | ||||||
| Crystal structure of the HIV-1 capsid protein C-terminal domain (146- 220) in complex with a cameli… |
Heteromer | |||||
| Assess | ||||||
| CryoEM structure of HIV-1 conserved Intasome Core | homo-8-mer | 4×MG; 2×DLU; | ||||
| Assess | ||||||
| HIV-CA Disulfide linked Hexamer bound to 11l capsid inhibitor. | homo-6-mer | 6×XBQ; | ||||
| Assess | ||||||
| X-ray Structure of Hexameric HIV-1 CA | homo-6-mer | |||||
| Assess | ||||||
| X-ray Structure of Hexameric HIV-1 CA | homo-6-mer | 6×EDO; | ||||
| Assess | ||||||
| HIV capsid hexamer with IP6 ligand | homo-6-mer | 6×IHP; | ||||
| Assess | ||||||
| X-ray Structure of Hexameric HIV-1 CA | homo-6-mer | |||||
| Assess | ||||||
| Disulfide stabilized HIV-1 CA hexamer in complex with PHENYL-L-PHENYLALANINAMIDE inhibitor | homo-6-mer | 6×1B0; | ||||
| Assess | ||||||
| HIV-CA Disulfide linked Hexamer bound to Quinazolin-4-one Scaffold inhibitor | homo-6-mer | 6×J6U; | ||||
| Assess | ||||||
| HIV-CA Disulfide linked Hexamer bound to Quinazolin-4-one Scaffold inhibitor | homo-6-mer | 6×K3L; | ||||
| Assess | ||||||
| CATALYTIC DOMAIN OF HIV-1 INTEGRASE | homo-6-mer | 6×MG; | ||||
| Assess | ||||||
| X-ray structure of pentameric HIV-1 CA | homo-5-mer | 10×IOD; | ||||
| Assess | ||||||
| Structure of tetrameric HIV-1 Strand Transfer Complex Intasome | homo-4-mer | 2×ZN; 2×MG; | ||||
| Assess | ||||||
| Crystal Structure of a Two-Domain Fragment of HIV-1 Integrase | homo-4-mer | 4×ZN; 4×K; 4×PO4; | ||||
| Assess | ||||||
| HIV capsid C-terminal domain | homo-4-mer | 1×EDO; | ||||
| Assess | ||||||
| CATALYTIC DOMAIN OF HIV-1 INTEGRASE | homo-3-mer | |||||
| Assess | ||||||
| TRIMERIC HIV-1 MATRIX PROTEIN | homo-3-mer | 3×SO4; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase Q151M:DNA:dGTP ternary complex | homo-2-mer | 1×GLC; 1×MG; 1×DGT; 2×GOL; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase Q151M:DNA:entecavir-triphosphate ternary complex | homo-2-mer | 1×GLC; 1×ET9; 1×MG; 2×GOL; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase Q151M:DNA binary complex | homo-2-mer | 1×GLC; 3×GOL; | ||||
| Assess | ||||||
| HIV capsid dimer structure | homo-2-mer | |||||
| Assess | ||||||
| Structure of HIV-1 integrase with native amino-terminal sequence | homo-2-mer | 2×ZN; 2×K; 2×PO4; | ||||
| Assess | ||||||
| CATALYTIC DOMAIN OF HIV-1 INTEGRASE: ORDERED ACTIVE SITE IN THE F185H CONSTRUCT | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 INTEGRASE CORE DOMAIN | homo-2-mer | 4×CAC; | ||||
| Assess | ||||||
| HIV Integrase in complex with Compound-15 | homo-2-mer | 2×MG; 2×GE7; | ||||
| Assess | ||||||
| Parallel screening of a low molecular weight compound library: do differences in methodology affect… | homo-2-mer | 2×0MB; 10×SO4; 9×EDO; 4×CL; 2×GOL; 2×TAM; | ||||
| Assess | ||||||
| Parallel screening of a low molecular weight compound library: do differences in methodology affect… | homo-2-mer | 6×SO4; 2×CL; 4×GOL; 2×ICO; 1×ACY; 1×EDO; | ||||
| Assess | ||||||
| Catalytic Core Domain of HIV-1 Integrase (F185K) bound with BI-224436 | homo-2-mer | 2×L3D; 2×EDO; 2×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 4×ACT; 3×CL; 5×EDO; 1×H75; 1×LYS; | ||||
| Assess | ||||||
| HIV Integrase core domain in complex with inhibitor 2-[2-(2-{3-[(4-{2-[(3-{2-[3-(carboxymethyl)-5-m… | homo-2-mer | 1×9I4; 4×IOD; 5×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 4×ACT; 4×NVU; | ||||
| Assess | ||||||
| Parallel screening of a low molecular weight compound library: do differences in methodology affect… | homo-2-mer | 8×SO4; 3×ACY; 2×GOL; 2×I2E; | ||||
| Assess | ||||||
| HIV integrase | homo-2-mer | 2×976; 2×P03; 4×PEG; 6×SO4; 2×CA; | ||||
| Assess | ||||||
| HIV integrase | homo-2-mer | 2×723; 8×PEG; 2×P03; 6×SO4; 2×CA; 2×CL; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain A128T Mutant Complexed with Allosteric Inhibitor | homo-2-mer | 4×ARS; 2×LF2; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 2×ACY; 1×EDO; 4×ZT2; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE: SIMILARITY TO OTHER POLYNUCLEOTIDYL T… | homo-2-mer | 4×CAC; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-[3-(3,… | homo-2-mer | 4×SO4; 2×PGE; 2×EJ9; 2×EDO; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor | homo-2-mer | 4×ARS; 2×LF2; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 1×CL; 2×ACY; | ||||
| Assess | ||||||
| Cyclic hexapeptide PKIDNG in complex with HIV-1 integrase | homo-2-mer | 4×CD; 2×CL; 6×SO4; | ||||
| Assess | ||||||
| HIV INTEGRASE CORE DOMAIN COMPLEXED WITH TETRAPHENYL ARSONIUM | homo-2-mer | 2×SO4; 2×CL; 2×TTA; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 3×ACY; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 4×ACY; 2×CL; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×GOL; 2×ACT; 2×HLR; | ||||
| Assess | ||||||
| Parallel screening of a low molecular weight compound library: do differences in methodology affect… | homo-2-mer | 4×SO4; 5×ACT; 2×EDO; 1×GOL; 2×AKH; | ||||
| Assess | ||||||
| Cyclic hexapeptide PKIDNp in complex with HIV-1 integrase | homo-2-mer | 4×CD; 2×CL; 6×SO4; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 8×SO4; 4×ACY; 2×NA; 2×O2N; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 1×CL; 2×EDO; 2×K5Q; | ||||
| Assess | ||||||
| Inhibitor resistant mutant catalytic core domain of HIV-1 Integrase | homo-2-mer | 4×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×CL; 2×ACT; 2×9PA; | ||||
| Assess | ||||||
| Parallel screening of a low molecular weight compound library: do differences in methodology affect… | homo-2-mer | 8×SO4; 3×EDO; 2×TAM; 2×Q6T; 1×ACY; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×CL; 1×ACY; 2×GOL; 2×ZSW; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×CL; 2×B0T; 1×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×ACT; 3×CL; 2×JDX; | ||||
| Assess | ||||||
| Parallel screening of a low molecular weight compound library: do differences in methodology affect… | homo-2-mer | 6×SO4; 2×ACY; 5×EDO; 2×TAM; 2×Z5P; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 3×CL; 2×ACY; | ||||
| Assess | ||||||
| HIV Integrase Core domain (IN) in complex with dimer-spanning ligand | homo-2-mer | 1×R2A; 6×IOD; 7×SO4; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor | homo-2-mer | 2×LF0; 6×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 1×CL; 2×DMS; 5×ACT; 2×RVN; 2×EDO; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 3×ACT; 2×IY7; | ||||
| Assess | ||||||
| HIV-1 INTEGRASE CORE DOMAIN | homo-2-mer | |||||
| Assess | ||||||
| Catalytic Core Domain of HIV-1 Integrase (F185K) | homo-2-mer | 8×SO4; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[4-(4-chl… | homo-2-mer | 2×LF8; 6×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×ACT; 2×NZL; | ||||
| Assess | ||||||
| Rapid development of potent inhibitors of the HIV integrase-LEDGF interaction by fragment-linking u… | homo-2-mer | 6×IOD; 12×SO4; 1×YAV; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain A128T Mutant Complexed with Allosteric Inhibitor | homo-2-mer | 2×0L9; 2×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 1×EDO; 2×5EY; 2×EE2; 1×ACT; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-[3-(3,… | homo-2-mer | 4×SO4; 2×PGE; 2×940; | ||||
| Assess | ||||||
| Core domain of HIV-1 integrase complexed with Mg++ and 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetra… | homo-2-mer | 2×MG; 1×100; | ||||
| Assess | ||||||
| Cryogenic structure of HIV-1 Integrase catalytic core domain by synchrotron | homo-2-mer | 4×CAC; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[6-(5-chl… | homo-2-mer | 2×LF9; 6×SO4; | ||||
| Assess | ||||||
| HIV INTEGRASE CORE DOMAIN COMPLEXED WITH A DERIVATIVE OF TETRAPHENYL ARSONIUM. | homo-2-mer | 2×SO4; 2×CL; 2×TTO; | ||||
| Assess | ||||||
| Cyclic hexapeptide cyc[NdPopPKID] in complex with HIV-1 integrase core domain | homo-2-mer | 4×CD; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[6-(5-chl… | homo-2-mer | 2×LF9; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-(2-(3-… | homo-2-mer | 6×SO4; 2×GZ9; | ||||
| Assess | ||||||
| Room temperature structure of HIV-1 Integrase catalytic core domain by serial femtosecond crystallo… | homo-2-mer | 4×CAC; | ||||
| Assess | ||||||
| HIV-1 INTEGRASE CORE DOMAIN COMPLEXED WITH MG++ | homo-2-mer | 2×MG; | ||||
| Assess | ||||||
| Cyclic hexapeptide CKIDNC in complex with HIV-1 integrase | homo-2-mer | 4×CD; 2×CL; 6×SO4; | ||||
| Assess | ||||||
| Cyclic hexapeptide PKZDNv in complex with HIV-1 integrase | homo-2-mer | 4×CD; 2×CL; 6×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 5×ACY; 1×EDO; 3×CL; 2×GOL; 2×V7H; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 4×SO4; 3×ACY; 2×O4N; 1×GOL; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 1×ACT; 2×CL; 2×QCH; 1×DMS; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 7×SO4; 3×ACT; 2×VXO; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×E4F; 2×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 3×ACT; 7×EDO; 2×GOL; 2×U2Z; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 2×CL; 2×GOL; 2×O3N; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 7×ACY; 2×1TD; 1×GOL; 1×EDO; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 4×ACY; 1×EDO; 4×C5Q; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 4×ACT; 4×ZT2; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×CL; 2×GOL; 2×O3N; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 3×ACY; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 2×ACY; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×CL; 2×GOL; 2×D0T; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 8×ACT; 3×EDO; 2×UJ6; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 5×ACT; 2×JNS; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×CL; 2×VL4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×CL; 2×GOL; 2×9NS; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 4×SO4; 2×ACY; 2×EDO; 2×GOL; 2×ZSV; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×ACT; 2×CL; 2×GOL; 2×2SS; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 4×ACT; 2×CL; 2×H39; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×ACY; 2×CL; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 3×EDO; 2×CL; 2×OM1; 1×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 2×ACY; 2×EDO; 2×GOL; 2×ZSV; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 7×SO4; 3×EDO; 2×OM1; 1×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 7×SO4; 2×ACY; 2×LOZ; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 2×ACY; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 7×SO4; 4×ACT; 2×K1T; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 2×THR; 6×SO4; 2×CL; 1×ACY; 2×GOL; 2×ZSW; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 9×SO4; 1×CL; 2×FYM; 1×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 4×ACT; 2×CL; 2×S3G; | ||||
| Assess | ||||||
| Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screenin… | homo-2-mer | 10×SO4; 7×ACY; 2×EDO; 2×CIW; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV integrase identified by fragment screening and s… | homo-2-mer | 6×SO4; 2×GOL; 2×PX3; 2×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 4×ACT; 2×CL; 2×L0Y; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×CL; 2×NFW; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×O5U; 2×ACT; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 2×ACY; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 4×ACY; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 2×ACY; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×ACT; 4×EDO; 4×IMV; | ||||
| Assess | ||||||
| Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screenin… | homo-2-mer | 4×SO4; 4×EDO; 2×CL; 2×ACY; 4×IMV; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×ACT; 2×CL; 2×7NV; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×Q31; 2×CL; 1×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 1×CL; 2×ACT; 2×G0T; | ||||
| Assess | ||||||
| Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 6×CDQ; 2×ACY; | ||||
| Assess | ||||||
| Cyclic hexapeptide cyc[NdPopPKID] in complex with HIV-1 integrase core domain | homo-2-mer | 4×CD; 2×CL; 4×SO4; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 2×ZT0; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 2×EDO; 2×GOL; 2×N44; 2×ACT; | ||||
| Assess | ||||||
| Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screenin… | homo-2-mer | 11×SO4; 2×CD9; 2×EDO; 6×ACY; | ||||
| Assess | ||||||
| Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screenin… | homo-2-mer | 8×SO4; 4×CBJ; 5×ACY; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 4×SO4; 7×ACY; 1×EDO; 2×ZT4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×3GM; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×CL; 3×EDO; 2×ACT; 2×CWU; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 2×ACT; 2×CL; 2×4VW; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 4×ACT; 4×CBJ; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 2×GOL; 2×IV2; 3×ACT; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 5×ACT; 2×OM3; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 5×ACT; 2×OM2; 1×CL; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 5×SO4; 2×ACT; 3×EDO; 2×GOL; 2×ONZ; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 7×SO4; 2×CL; 2×4D2; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 2×ACY; 1×EDO; 1×CL; 2×GOL; 2×8P3; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×WOP; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 4×SO4; 2×ACY; 2×GOL; 2×O3N; | ||||
| Assess | ||||||
| Crystal structures of novel allosteric peptide inhibitors of HIV integrase in the LEDGF binding site | homo-2-mer | 8×SO4; 2×CL; 2×ACY; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×ACT; 2×NZL; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 6×SO4; 4×ACT; 2×CL; 2×S8Y; | ||||
| Assess | ||||||
| Small molecule inhibitors of the LEDGF site of HIV type 1 integrase identified by fragment screenin… | homo-2-mer | 6×SO4; 2×ACT; 2×OM3; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain (CCD) F185H Mutant Complexed with STP03-0404 | homo-2-mer | 2×WBV; | ||||
| Assess | ||||||
| HIV Integrase in complex with Compound-14 | homo-2-mer | 4×1PE; 2×PEG; 2×QCG; 6×SO4; | ||||
| Assess | ||||||
| HIV1 catalytic core domain in complex with inhibitor: (2~{S})-2-[3-(3,4-dihydro-2~{H}-chromen-6-yl)… | homo-2-mer | 6×SO4; 2×7SK; | ||||
| Assess | ||||||
| HIV1 catalytic core domain in complex with an inhibitor (2~{S})-2-[3-(3,4-dihydro-2~{H}-chromen-6-y… | homo-2-mer | 2×7SK; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain Mutant (KGD) in Complex with Inhibitor GRL-142 | homo-2-mer | 1×7OA; 1×SO4; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 2×CL; 4×ACY; 2×Y7N; | ||||
| Assess | ||||||
| Interrogating HIV integrase for compounds that bind- a SAMPL challenge | homo-2-mer | 8×SO4; 8×ACT; 2×X0P; | ||||
| Assess | ||||||
| Dual inhibition of HIV-1 replication by Integrase-LEDGF allosteric inhibitors is predominant at pos… | homo-2-mer | 2×MG; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 INTEGRASE COMPLEXED WITH Compound-2a AKA (2S)-2-(TERT-BUTOXY)-2-[7-(4,4-… | homo-2-mer | 2×KZD; 6×SO4; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 INTEGRASE COMPLEXED WITH (2S)-2-(TERT-BUTOXY)-2-(5-{2-[(2-CHLORO-6-M ETH… | homo-2-mer | 2×O20; 6×SO4; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Integrase with a non-catayltic site inhibitor | homo-2-mer | 2×TQ2; | ||||
| Assess | ||||||
| HIV Integrase CORE domain in complex with 2-{2-[2-(3-{[4-(2-{[(3-{2-[3-(carboxymethyl)-5-methyl-1-b… | homo-2-mer | 6×SO4; 5×IOD; 1×6I2; | ||||
| Assess | ||||||
| HIV Integrase in complex with Compound-25 | homo-2-mer | 6×SO4; 2×GEI; 2×GOL; | ||||
| Assess | ||||||
| Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors | homo-2-mer | 2×RWR; 2×MG; 2×SO4; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Integrase with a non-catayltic site inhibitor | homo-2-mer | 2×TQX; | ||||
| Assess | ||||||
| Dual inhibition of HIV-1 replication by Integrase-LEDGF allosteric inhibitors is predominant at pos… | homo-2-mer | 2×LF0; 2×MG; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain (CCD) in Complex with a Fragment-Derived Allosteric Inhibitor | homo-2-mer | 4×6W6; | ||||
| Assess | ||||||
| HIV-1 Integrase catalytic core domain complexed with allosteric inhibitor STP03-0404 | homo-2-mer | 2×WBV; | ||||
| Assess | ||||||
| CACODYLATED CATALYTIC DOMAIN OF HIV-1 INTEGRASE | homo-2-mer | |||||
| Assess | ||||||
| HIV Integrase core domain in complex with inhibitor (5-methyl-1-benzofuran-3-yl)acetic acid | homo-2-mer | 14×IOD; 2×RQG; 4×SO4; | ||||
| Assess | ||||||
| HIV Integrase core domain in complex with inhibitor 2-(5-methyl-2-(2-(thiophen-2-yl)ethynyl)-1-benz… | homo-2-mer | 4×SO4; 8×IOD; 2×SJY; | ||||
| Assess | ||||||
| HIV Integrase core domain in complex with inhibitor 2-(5-(3-fluorophenyl)-2-(2-(thiophen-2-yl)ethyn… | homo-2-mer | 4×SO4; 10×IOD; 2×XFS; | ||||
| Assess | ||||||
| HIV Integrase Core domain (IN) in complex with [5-(3-fluorophenyl)-1-benzofuran-3-yl]acetic acid | homo-2-mer | 6×SO4; 8×IOD; 2×R7J; | ||||
| Assess | ||||||
| HIV Integrase core domain in complex with inhibitor 2-(2-ethynyl-5-methyl-1-benzofuran-3-yl)acetic … | homo-2-mer | 2×S0Y; 2×SO4; 10×IOD; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 CA146 A92E real cell | homo-2-mer | 2×CL; | ||||
| Assess | ||||||
| X-ray crystal structure of wild type HIV-1 protease in complex with GRL-004 | homo-2-mer | 2×NKA; | ||||
| Assess | ||||||
| X-ray crystal structure of wild type HIV-1 protease in complex with GRL-001 | homo-2-mer | 6×EDO; 2×JDY; | ||||
| Assess | ||||||
| X-ray crystal structure of wild type HIV-1 protease in complex with GRL-003 | homo-2-mer | 2×JDV; | ||||
| Assess | ||||||
| X-ray crystal structure of wild type HIV-1 protease in complex with GRL-002 | homo-2-mer | 2×NJY; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PD4 (LR4-23) | homo-2-mer | 1×XUM; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PD5 (LR4-22) | homo-2-mer | 1×XUP; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PD4 (LR4-23) | homo-2-mer | 1×XUM; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU1 (LR3-46) | homo-2-mer | 1×XUS; 4×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with LR4-15 | homo-2-mer | 2×SO4; 1×YTY; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU5 (LR4-47) | homo-2-mer | 1×XVJ; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU5 (LR4-47) | homo-2-mer | 1×XVJ; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PD5 (LR4-22) | homo-2-mer | 1×SO4; 1×XUP; | ||||
| Assess | ||||||
| HIV Protease (PR) with TL-3 in the active site and (Z)-N-(thiazol-2-yl)-N'-tosylcarbamimidate in th… | homo-2-mer | 1×3TL; 2×7GC; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR3-97 | homo-2-mer | 1×ORV; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR2-26 | homo-2-mer | 1×NJ1; 4×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR3-55 | homo-2-mer | 6×SO4; 1×YWS; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR3-68 | homo-2-mer | 3×SO4; 1×YWM; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 L89V, L90M Mutant in complex with darunavir | homo-2-mer | 2×SO4; 1×017; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with TMC-126 | homo-2-mer | 7×SO4; 1×DJR; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with NR02-79 | homo-2-mer | 1×YUA; 4×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with LR3-48 | homo-2-mer | 4×SO4; 1×YWP; | ||||
| Assess | ||||||
| WT HIV-1 Protease in Complex with Phosphonated UMass6 (PU6) | homo-2-mer | 3×SO4; 1×TK7; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with GRL-98065 | homo-2-mer | 10×SO4; 1×065; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR3-28 | homo-2-mer | 1×OQG; 3×SO4; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 protease in complex with lactam derivative 2 | homo-2-mer | 2×GOL; 1×8LT; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with LR3-68 | homo-2-mer | 3×SO4; 1×YWM; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR-99 | homo-2-mer | 1×SO4; 1×NE7; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR-84 | homo-2-mer | 1×SO4; 1×NEJ; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with GRL-98065 | homo-2-mer | 6×SO4; 1×065; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU10 (LR4-07) | homo-2-mer | 4×SO4; 1×XVV; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with UMass9 | homo-2-mer | 5×SO4; 1×K2E; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with a Darunavir Derivative | homo-2-mer | 6×SO4; 1×XUY; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR2-18 | homo-2-mer | 5×SO4; 1×NF7; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with UMass5 | homo-2-mer | 1×K19; 3×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU6 (LR3-66) | homo-2-mer | 3×SO4; 1×TK7; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with GS-8374 | homo-2-mer | 5×SO4; 1×KGQ; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU4 (LR2-78) | homo-2-mer | 3×SO4; 1×XVM; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with LR3-55 | homo-2-mer | 1×YWS; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with UMass8 | homo-2-mer | 2×SO4; 1×F53; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU2 (LR2-79) | homo-2-mer | 2×SO4; 1×XUV; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR2-20 | homo-2-mer | 5×SO4; 1×NJG; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with NR01-141 | homo-2-mer | 1×YUJ; 3×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with LR4-44 | homo-2-mer | 1×YUP; 3×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-32 | homo-2-mer | 1×SO4; 1×OQY; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU9 (LR2-80) | homo-2-mer | 4×SO4; 1×XW4; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR3-48 | homo-2-mer | 6×SO4; 1×YWP; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU8 (LR4-06) | homo-2-mer | 1×XVY; 3×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR3-43 | homo-2-mer | 1×OO4; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 L90M Mutant in complex with darunavir | homo-2-mer | 5×SO4; 1×017; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with NR02-73 | homo-2-mer | 1×YUD; 4×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU2 (LR2-79) | homo-2-mer | 1×SO4; 1×XUV; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with NR02-79 | homo-2-mer | 1×YUA; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with LR2-91 | homo-2-mer | 6×SO4; 1×NJM; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU3 (LR3-69) | homo-2-mer | 3×SO4; 1×XVP; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-43 | homo-2-mer | 1×OPJ; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-35 | homo-2-mer | 2×SO4; 1×OQV; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU7 (LR3-67) | homo-2-mer | 7×SO4; 1×XVS; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-44 | homo-2-mer | 2×SO4; 1×OP7; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU3 (LR3-69) | homo-2-mer | 1×XVP; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU10 (LR4-07) | homo-2-mer | 1×XVV; 4×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-42 | homo-2-mer | 1×OQ7; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with NR02-73 | homo-2-mer | 4×SO4; 1×YUD; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with a Darunavir Derivative | homo-2-mer | 5×SO4; 1×XUY; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with LR4-33 | homo-2-mer | 5×SO4; 1×YUM; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU8 (LR4-06) | homo-2-mer | 5×SO4; 1×XVY; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-19 | homo-2-mer | 3×SO4; 1×NG4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-20 | homo-2-mer | 2×SO4; 1×NJG; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with NR01-141 | homo-2-mer | 5×SO4; 1×YUJ; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-18 | homo-2-mer | 1×NF7; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with UMass10 | homo-2-mer | 1×A61; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR4-41 | homo-2-mer | 3×SO4; 1×OR1; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with UMass3 | homo-2-mer | 2×SO4; 1×K2A; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with UMass4 | homo-2-mer | 4×SO4; 1×K20; | ||||
| Assess | ||||||
| HIV-1 Protease (I84V) in Complex with PU7 (LR3-67) | homo-2-mer | 5×SO4; 1×XVS; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with GS-8374 | homo-2-mer | 4×SO4; 1×KGQ; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-41 | homo-2-mer | 1×SO4; 1×OQP; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR-100 | homo-2-mer | 1×NFJ; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with Lopinavir | homo-2-mer | 8×SO4; 1×AB1; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with TMC-126 | homo-2-mer | 5×SO4; 1×DJR; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR-76 | homo-2-mer | 1×NJ4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-25 | homo-2-mer | 1×NJJ; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR-85 | homo-2-mer | 1×NF4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR3-95 | homo-2-mer | 5×SO4; 1×OQA; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with UMass7 | homo-2-mer | 7×SO4; 1×K2D; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU4 (LR2-78) | homo-2-mer | 2×SO4; 1×XVM; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU9 (LR2-80) | homo-2-mer | 1×XW4; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with PU1 (LR3-46) | homo-2-mer | 3×SO4; 1×XUS; | ||||
| Assess | ||||||
| HIV Protease (PR) with TL-3 in active site and 4-methylbenzene-1,2-diamine in exosite | homo-2-mer | 2×3TL; 2×9AY; 6×DMS; | ||||
| Assess | ||||||
| HIV Protease (PR) in open form with Mg2+ in active site and HIVE-9 in eye site | homo-2-mer | 2×HV9; 2×MG; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACE… | homo-2-mer | 2×CL; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-21 | homo-2-mer | 3×SO4; 1×NJ7; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-26 | homo-2-mer | 2×SO4; 1×NJ1; | ||||
| Assess | ||||||
| HIV-1 Protease WT (NL4-3) in Complex with UMass2 | homo-2-mer | 2×SO4; 1×K14; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR3-29 | homo-2-mer | 1×OQD; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR2-91 | homo-2-mer | 5×SO4; 1×NJM; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 protease in complex with macrocyclic peptide | homo-2-mer | 1×MG; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 protease in complex with lactam derivative 1 | homo-2-mer | 2×8OC; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 WT in Complex with LR-82 | homo-2-mer | 1×NJA; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, V82F, I84V Mutant in complex with da… | homo-2-mer | 1×SO4; 1×017; | ||||
| Assess | ||||||
| X-RAY CRYSTAL STRUCTURE OF THE HIV PROTEASE COMPLEX WITH L-700,417, AN INHIBITOR WITH PSEUDO C2 SYM… | homo-2-mer | 2×VAC; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 Protease NL4-3 L89V Mutant in complex with darunavir | homo-2-mer | 1×017; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, L76V, V82F, I84V Mutant in complex w… | homo-2-mer | 1×017; | ||||
| Assess | ||||||
| HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, I54L, A71V, L76V, V82F, I84V Mutant in com… | homo-2-mer | 1×017; | ||||
| Assess | ||||||
| Discovery of New HIV Protease Inhibitors with Potential for Convenient Dosing and Reduced Side Effe… | homo-2-mer | 1×LK0; | ||||
| Assess | ||||||
| Design, activity and 2.8 Angstroms crystal structure of a C2 symmetric inhibitor complexed to HIV-1… | homo-2-mer | 1×0E9; | ||||
| Assess | ||||||
| Dimer of HIV-1 Gag CTD-SP1 fragment | homo-2-mer | |||||
| Assess | ||||||
| THREE-DIMENSIONAL STRUCTURE OF ASPARTYL PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS HIV-1 | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (Y169S) | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (Y169A) | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (L211S) | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (L211S) in complex with an inhibitor of particle assembly (CA… | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (Y169L) | homo-2-mer | 2×SO4; | ||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (N183A) | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (Y169A) in complex with an inhibitor of particle assembly (CA… | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (E187A) | homo-2-mer | |||||
| Assess | ||||||
| STRUCTURE OF THE HIV-1 CAPSID PROTEIN DIMERIZATION DOMAIN AT 2.6A RESOLUTION | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of synthetic HIV-1 capsid C-terminal domain (CCA) | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 CAPSID PROTEIN C-TERMINAL FRAGMENT PLUS GAG P2 DOMAIN | homo-2-mer | |||||
| Assess | ||||||
| HIV CAPSID C-TERMINAL DOMAIN | homo-2-mer | |||||
| Assess | ||||||
| HIV CAPSID C-TERMINAL DOMAIN (CAC146) | homo-2-mer | |||||
| Assess | ||||||
| SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (D FORM), NMR, 40 STRUCTU… | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (E FORM), NMR, 38 STRUCTU… | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Structure of a monomeric mutant of the HIV-1 capsid protein | monomer | |||||
| Assess | ||||||
| HIV-1 capsid monomer structure | monomer | |||||
| Assess | ||||||
| The structure of the W184AM185A mutant of the HIV-1 capsid protein | monomer | |||||
| Assess | ||||||
| Pseudo-atomic model of the HIV-1 CA hexameric lattice | monomer | |||||
| Assess | ||||||
| The Crystal Structure of integrase from Biortus | monomer | 6×SO4; 1×ACT; | ||||
| Assess | ||||||
| MOBILITY OF AN HIV-1 INTEGRASE ACTIVE SITE LOOP IS CORRELATED WITH CATALYTIC ACTIVITY | monomer | 2×CAC; 1×SO4; | ||||
| Assess | ||||||
| MOBILITY OF AN HIV-1 INTEGRASE ACTIVE SITE LOOP IS CORRELATED WITH CATALYTIC ACTIVITY | monomer | 2×CAC; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytical Core Domain | monomer | 2×ARS; 2×SO4; 1×0L9; | ||||
| Assess | ||||||
| MOBILITY OF AN HIV-1 INTEGRASE ACTIVE SITE LOOP IS CORRELATED WITH CATALYTIC ACTIVITY | monomer | 2×CAC; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 integrase catalytic core domain in complex with (2S)-2-(tert-Butoxy)-2-(… | monomer | 2×SO4; 1×8Z3; 1×GOL; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain F185H Mutant Complexed with BKC-110 | monomer | 1×QD6; | ||||
| Assess | ||||||
| HIV-1 Integrase Catalytic Core Domain in Complex with an Allosteric Inhibitor, 3-(1H-pyrrol-1-yl)-2… | monomer | 1×DMS; 2×6XI; | ||||
| Assess | ||||||
| Crystal structure of the complex of PF-3450074 with an engineered HIV capsid N terminal domain | monomer | 1×1B0; | ||||
| Assess | ||||||
| Crystal Structure of the N-Terminal Domain of HIV-1 Capsid in Complex With Inhibitor BD3 | monomer | 1×0OE; 1×0OF; 4×IOD; | ||||
| Assess | ||||||
| Crystal Structure of the N-Terminal Domain of HIV-1 Capsid in Complex With Inhibitor BM4 | monomer | 1×0OE; 1×0OG; | ||||
| Assess | ||||||
| Re-refinement of CAP-1 HIV-CA complex | monomer | 1×CL; 2×ZN; 1×JPR; | ||||
| Assess | ||||||
| Joint refinement of the HIV-1 CA-NTD in complex with the assembly inhibitor CAP-1 | monomer | 1×JPR; | ||||
| Assess | ||||||
| Xray Structure of Gag133-278 | monomer | 1×FLC; | ||||
| Assess | ||||||
| HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 MATRIX PROTEIN | monomer | |||||
| Assess | ||||||
| Structure of HIV-1 myr(-) matrix protein in complex with 1,2-dioctanoyl-sn-phosphatidyl-L-serine | monomer | 1×8SP; | ||||
| Assess | ||||||
| HIV-1 Myristoylated Matrix | monomer | |||||
| Assess | ||||||
| Structure of HIV-1 myr(-) matrix protein in complex with 1,2-dioctanoyl-sn-phosphatidylcholine | monomer | 1×PC8; | ||||
| Assess | ||||||
| Solution structure of HIV-1 myrMA bound to di-C4-phosphatidylinositol-(4,5)-bisphosphate | monomer | 1×MYR; 1×PBU; | ||||
| Assess | ||||||
| Structure of the HIV-1 Matrix protein bound to di-C8-phosphatidylinositol-(4,5)-bisphosphate | monomer | 1×PIO; | ||||
| Assess | ||||||
| Solution structure of the HIV-1 myristoylated Matrix protein | monomer | 1×MYR; | ||||
| Assess | ||||||
| Solution structure of the HIV-1 MA protein | monomer | |||||
| Assess | ||||||
| Structure of the HIV-1 matrix protein bound to di-C4-phosphatidylinositol-(4,5)-bisphosphate | monomer | 1×PBU; | ||||
| Assess | ||||||
| Crystal structure of HIV matrix residues 1-111 in complex with inhibitor | monomer | 1×SO4; 1×1ML; | ||||
| Assess | ||||||
| Solution Structure of the W184A/M185A Mutant of the Carboxy-terminal Dimerization Domain of the HIV… | monomer | |||||
| Assess | ||||||
| Solution Structure of A Double Mutant of The Carboxy-terminal Dimerization Domain of The HIV-1 Caps… | monomer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (N183A) in complex with an inhibitor of particle assembly (CA… | monomer | |||||
| Assess | ||||||
| HIV-1 capsid C-terminal domain mutant (E187A) in complex with an inhibitor of particle assembly (CA… | monomer | |||||
| Assess | ||||||
| NMR solution structure of HIV-1 nucleocapsid protein in complex with an inhibitor displaying a 2 in… | monomer | 2×ZN; 2×1HF; | ||||
| Assess | ||||||
| Crystal Structure of the C-terminal domain of the HIV-1 Integrase (PNL4-3) | monomer | 1×NI; | ||||
| Assess | ||||||
9 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6rwm.1.A | homo-12-mer | 0.76 | 8×ZN; | 75.35 | ||
| Assess | ||||||
| 6rwl.1.B | monomer | 0.74 | 1×ZN; | 75.35 | ||
| Assess | ||||||
| 6rwl.1.A | monomer | 0.73 | 1×ZN; | 75.35 | ||
| Assess | ||||||
| 6v3k.3.A | homo-4-mer | 0.73 | 96.24 | |||
| Assess | ||||||
| 7sep.1.A | homo-2-mer | 0.71 | 96.90 | |||
| Assess | ||||||
| 5u1c.1.A | homo-4-mer | 0.71 | 95.86 | |||
| Assess | ||||||
| 1l6n.1.A | monomer | 0.70 | 100.00 | |||
| Assess | ||||||
| 7t15.1.E | homo-6-mer | 0.69 | 84.85 | |||
| Assess | ||||||
| 7asl.1.A | homo-18-mer | 0.66 | 97.87 | |||
| Assess | ||||||